Diabetes Mellitus
Conditions
Keywords
Diabetes Mellitus, health literacy, patient activation, goals of care
Brief summary
This hybrid effectiveness/implementation trial will be conducted in two phases over four years. In Phase 1, the investigators will evaluate the process of implementing a collaborative, diabetes goal-setting intervention (Empowering Patients in Chronic Care \[EPIC\]) personalized to self-reported patient activation and functional health literacy (FHL) levels into routine primary care practices. In Phase 2, the investigators will conduct a randomized, clinical trial to compare the effectiveness of EPIC to enhanced usual care (EUC). In Phase 2, the investigators will conduct a randomized clinical trial enrolling 284 Veterans with poorly controlled diabetes defined by average hemoglobin A1c over the last six months of \>= 8% to receive EPIC or enhanced usual care (EUC). Consented subjects will be allocated evenly between EPIC and EUC. EPIC consists of six 1-hour group sessions focusing on 1) Your Health, Your Values, 2) Diabetes ABCs, 3) Setting Goals and Making Action Plans, 4) Communication with Your Health Care Provider, 5) Staying Committed to Your Goals, and 6) Reviewing and Planning for the Future. After each group session, a one-on-one session between a designated PACT member and patient participants will focus on collaborative goal-setting. Patients randomized to EUC will be referred to the PACT RN Care Manager for diabetes management, and will also receive a packet of educational materials regarding diabetes management, including a letter delineating the diabetes management resources available at their facility. Study measurements using self-reported questionnaires and blood tests to assess blood sugar control will be obtained at baseline, post-intervention, and post-six month maintenance period.
Detailed description
Project Background: Diabetes mellitus is a highly prevalent chronic condition, affecting one in four Veterans who use the Veterans Affairs (VA) health care system. Self-management skills are critical for controlling diabetes and reducing its cardiovascular sequela. Providing diabetic patients with effective self-management training and support can be challenging due to time constraints at primary care encounters and limited clinician training with behavior change. The investigators have previously demonstrated that a group-based, VA primary care intervention to help patients set highly effective, evidence-based diabetes goals had a positive impact on both diabetes self-efficacy and hemoglobin (Hb) A1c levels. This study aims to evaluate the process of implementing a collaborative goal-setting intervention personalized to patient activation and health literacy levels (i.e. Empowering Patients in Chronic Care \[EPIC\]) into routine PACT care and to evaluate the effectiveness of this intervention relative to usual care. Project Objectives: Specific Aim 1: Assess effective processes for and costs associated with implementing a collaborative diabetes goal-setting intervention personalized to patient activation and FHL (i.e., EPIC) into the routine workflows of PACTs. H1: Formative measures within the PARIHS framework (evidence, context, facilitation) will be associated with implementation of EPIC (defined by reach, adoption, cost effectiveness, and fidelity measures) into routine PACT care. Specific Aim 2: Evaluate the effectiveness of delivering collaborative goal-setting personalized to patient activation and FHL on clinical (HbA1c) and patient-centered (Diabetes Distress Scale) outcomes among eligible patients in enrolled PACTs. H2: Patients receiving collaborative goal-setting personalized to activation and FHL levels will have significant improvements in a) HbA1c and b) Diabetes Distress Scale levels, respectively, at post-intervention compared with patients receiving enhanced usual care. H3: Patients receiving collaborative goal-setting personalized to activation and FHL levels will maintain significant improvements in a) HbA1c and b) Diabetes Distress Scale levels at post-maintenance follow-up, respectively, compared with patients receiving enhanced usual care. Project Methods: In Phase 1 of the study, the investigators will implement EPIC into routine PACT care. The investigators will conduct a mixed-methods formative evaluation that includes 33-48 key informant interviews with VA leadership, clinicians, and staff and an assessment of organizational readiness for change. This evaluation will identify how group and one-on-one sessions of EPIC can best be implemented into routine workflows of PACT. In Phase 2, the investigators will conduct a randomized clinical trial enrolling 284 patients with poorly controlled diabetes defined by average hemoglobin A1c of 8% to receive EPIC or enhanced usual care. The patient will serve as the unit of randomization. EPIC consists of six 1-hour group sessions focusing on 1) Your Health, Your Values, 2) Diabetes ABCs, 3) Setting Goals and Making Action Plans, 4) Communication with Your Health Care Provider, 5) Staying Committed to Your Goals, and 6) Reviewing and Planning for the Future. After each group session, a one-on-one session between a designated PACT member and patient participants will focus on collaborative goal-setting. Designated PACT members will be trained to personalize goal-setting using patient-reported activation and health literacy data. The investigators will collect laboratory and survey data at baseline, post-intervention, and post-maintenance phase. The investigators will evaluate the effectiveness of personalized goal-setting compared to enhanced usual care on clinical (e.g., hemoglobin A1c) and patient-centered (e.g., Diabetes Distress Scale) outcomes.
Interventions
EPIC group training sessions consisting of 6 one-hour group sessions occurring over a 6-month period. Group sessions will consist of behavioral coaching focused on diabetes management. Following each group-session, patients enrolled in the intervention arm will meet with a designated member of their primary care team to personalize diabetes goals and action plans.
Patients randomized to EUC will be referred to the PACT RN Care Manager for diabetes management, and will also receive a packet of educational materials regarding diabetes management, including a letter delineating the diabetes management resources available at their facility.
Sponsors
Study design
Eligibility
Inclusion criteria
* Veterans receiving primary care at VA study sites who are enrolled in the panels of participating primary care teams * Veterans with ICD-9-CM and/or ICD-10 codes indicating a diagnosis of diabetes * Veterans with an average HbA1c level \> 8% in the prior 6 months
Exclusion criteria
The investigators will exclude Veterans with the following clinical conditions that would render participation in a group clinic inappropriate: * metastatic cancer or receiving hospice care * limited life expectancy * clinician recommendations to not titrate therapy due to prior history of significant hypoglycemic events * age \<18 years * active bipolar or psychotic disorder The investigators will also exclude Veterans, who at the time of screening: * cannot attend monthly group clinic sessions due to transportation or availability barriers * have significant cognitive impairment * have active substance-abuse disorders * are not comfortable discussing their health and health care in a peer-group setting Patients will be secondarily excluded if their HbA1C level falls below 7.5% at baseline.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in Percent Glycosylated Hemoglobin (HbA1c) Levels During Intervention | HbA1c levels will be measured at baseline, four months, and ten months. | Measures of HbA1c will be taken to assess average blood glucose levels throughout the study as an indicator of diabetes control. |
| Change in Diabetes Specific Quality of Life | Diabetes specific quality of life will be measured at baseline, four months, and ten months. | The Diabetes Distress Scale (DDS) will be used to assess diabetes quality of life throughout the study. Minimum value: 1; Maximum value: 6. Higher scores indicate a higher level of diabetes distress. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Arm 1: Empowering Patients in Chronic Care (EPIC) Patients in the intervention arm will receive the Empowering Patients in Chronic Care group training sessions consisting of 6 one-hour group sessions occurring over a 6-month period. Group sessions will consist of behavioral coaching focused on diabetes management. Following each group-session, patients enrolled in the intervention arm will meet with a designated member of their primary care team to personalize diabetes goals and action plans.
Empowering Patients in Chronic Care (EPIC): EPIC group training sessions consisting of 6 one-hour group sessions occurring over a 6-month period. Group sessions will consist of behavioral coaching focused on diabetes management. Following each group-session, patients enrolled in the intervention arm will meet with a designated member of their primary care team to personalize diabetes goals and action plans. | 140 |
| Arm 2: Enhanced Usual Care (EUC) The Enhanced Usual Care (EUC) arm will serve as a concurrent control group to compare to the intervention arm of the study. Patients randomized to EUC will be referred to the PACT RN Care Manager for diabetes management, and will also receive a packet of educational materials regarding diabetes management, including a letter delineating the diabetes management resources available at their facility.
Enhanced Usual Care (EUC): Patients randomized to EUC will be referred to the PACT RN Care Manager for diabetes management, and will also receive a packet of educational materials regarding diabetes management, including a letter delineating the diabetes management resources available at their facility. | 140 |
| Total | 280 |
Baseline characteristics
| Characteristic | Arm 1: Empowering Patients in Chronic Care (EPIC) | Arm 2: Enhanced Usual Care (EUC) | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 94 Participants | 91 Participants | 185 Participants |
| Age, Categorical Between 18 and 65 years | 46 Participants | 49 Participants | 95 Participants |
| Age, Continuous | 67.39 Years STANDARD_DEVIATION 8.57 | 66.94 Years STANDARD_DEVIATION 8.34 | 67.17 Years STANDARD_DEVIATION 8.44 |
| Diabetes Distress Scale (DDS) | 2.41 Units on a scale STANDARD_DEVIATION 1.05 | 2.45 Units on a scale STANDARD_DEVIATION 1.02 | 2.43 Units on a scale STANDARD_DEVIATION 1.03 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 22 Participants | 11 Participants | 33 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 116 Participants | 125 Participants | 241 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 2 Participants | 4 Participants | 6 Participants |
| Percent Glycosylated Hemoglobin (HbA1c) | 9.11 Percent/DCCT STANDARD_DEVIATION 1.6 | 9.06 Percent/DCCT STANDARD_DEVIATION 1.32 | 9.08 Percent/DCCT STANDARD_DEVIATION 1.46 |
| Region of Enrollment United States | 140 Participants | 140 Participants | 280 Participants |
| Sex: Female, Male Female | 9 Participants | 7 Participants | 16 Participants |
| Sex: Female, Male Male | 131 Participants | 133 Participants | 264 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 140 | 4 / 140 |
| other Total, other adverse events | 0 / 140 | 0 / 140 |
| serious Total, serious adverse events | 0 / 140 | 0 / 140 |
Outcome results
Change in Diabetes Specific Quality of Life
The Diabetes Distress Scale (DDS) will be used to assess diabetes quality of life throughout the study. Minimum value: 1; Maximum value: 6. Higher scores indicate a higher level of diabetes distress.
Time frame: Diabetes specific quality of life will be measured at baseline, four months, and ten months.
Population: Seven participants did not complete the DDS at baseline. Therefore, sample sizes for DDS are lower than for HbA1c.~Although not all of the 138/135 per group with DDS at baseline completed each the post-intervention and maintenance assessments, intent to treat analyses were conducted which enabled us to use the full number across time points.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Arm 1: Empowering Patients in Chronic Care (EPIC) | Change in Diabetes Specific Quality of Life | Baseline | 2.41 Units On A Scale | Standard Deviation 1.05 |
| Arm 1: Empowering Patients in Chronic Care (EPIC) | Change in Diabetes Specific Quality of Life | 10 Months | 1.96 Units On A Scale | Standard Deviation 0.76 |
| Arm 1: Empowering Patients in Chronic Care (EPIC) | Change in Diabetes Specific Quality of Life | 4 Months | 2.02 Units On A Scale | Standard Deviation 0.81 |
| Arm 2: Enhanced Usual Care (EUC) | Change in Diabetes Specific Quality of Life | Baseline | 2.45 Units On A Scale | Standard Deviation 1.02 |
| Arm 2: Enhanced Usual Care (EUC) | Change in Diabetes Specific Quality of Life | 10 Months | 2.27 Units On A Scale | Standard Deviation 1.05 |
| Arm 2: Enhanced Usual Care (EUC) | Change in Diabetes Specific Quality of Life | 4 Months | 2.30 Units On A Scale | Standard Deviation 0.99 |
Changes in Percent Glycosylated Hemoglobin (HbA1c) Levels During Intervention
Measures of HbA1c will be taken to assess average blood glucose levels throughout the study as an indicator of diabetes control.
Time frame: HbA1c levels will be measured at baseline, four months, and ten months.
Population: Although not all of the 140 per group with HbA1c at baseline completed each the post-intervention and maintenance assessments, intent to treat analyses were conducted which enabled us to use the full 140 across time points.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Arm 1: Empowering Patients in Chronic Care (EPIC) | Changes in Percent Glycosylated Hemoglobin (HbA1c) Levels During Intervention | 10 Months | 8.68 Percentage/DCCT | Standard Deviation 1.53 |
| Arm 1: Empowering Patients in Chronic Care (EPIC) | Changes in Percent Glycosylated Hemoglobin (HbA1c) Levels During Intervention | Baseline | 9.11 Percentage/DCCT | Standard Deviation 1.6 |
| Arm 1: Empowering Patients in Chronic Care (EPIC) | Changes in Percent Glycosylated Hemoglobin (HbA1c) Levels During Intervention | 4 Months | 8.61 Percentage/DCCT | Standard Deviation 1.27 |
| Arm 2: Enhanced Usual Care (EUC) | Changes in Percent Glycosylated Hemoglobin (HbA1c) Levels During Intervention | 4 Months | 9.04 Percentage/DCCT | Standard Deviation 1.7 |
| Arm 2: Enhanced Usual Care (EUC) | Changes in Percent Glycosylated Hemoglobin (HbA1c) Levels During Intervention | 10 Months | 8.79 Percentage/DCCT | Standard Deviation 1.55 |
| Arm 2: Enhanced Usual Care (EUC) | Changes in Percent Glycosylated Hemoglobin (HbA1c) Levels During Intervention | Baseline | 9.06 Percentage/DCCT | Standard Deviation 1.32 |